An Israeli company’s experimental blood test can detect dementia while the disease is still mild enough to treat more effectively.
Blood test for Alzheimer’s
“Today one of the main weaknesses in the Alzheimer’s area is that patients don’t find out until it’s too late,” says Ilya Budik, CEO of
NeuroQuest, an Israeli company developing a novel blood test for early detection of the most common cause of dementia worldwide.
“There are many new therapies under development, and the most successful trials are showing the earlier a patient is treated, the better likelihood of responding to the treatment,” he says.
A portfolio company of the government-supported Misgav Venture Accelerator in northern Israel, NeuroQuest recently received $500,000 in a funding round led by the InterTech Group in South Carolina and the Maryland/Israel Trendlines Fund.
This half a million dollars will enable NeuroQuest to progress towards a validation clinical trial at four US medical centers, and to establish a US development center, possibly alongside its South Carolina partners.
More...
View Comments
